Tissue penetration of telavancin after intravenous administration in healthy subjects.
The pharmacokinetic disposition of telavancin administered 7.5 mg/kg of body weight every 24 h was determined in plasma and skin blister fluid. The mean penetration of telavancin into blister fluid was 40%. This study reveals that adequate concentrations are achieved in both plasma and blister fluid for pathogens frequently implicated in skin and soft tissue infections.
Sun
Heather K
HK
Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA.
Duchin
Kenneth
K
Nightingale
Charles H
CH
Shaw
Jeng-Pyng
JP
Seroogy
Julie
J
Nicolau
David P
DP
D000328:Adult; D000617:Aminoglycosides / Q000493:pharmacokinetics*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D019540:Area Under Curve; D006801:Humans; D007262:Infusions, Intravenous; D000077427:Lipoglycopeptides; D008875:Middle Aged; D010539:Permeability; D011485:Protein Binding; D051381:Rats
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077427:Lipoglycopeptides; C487637:telavancin